WO2005102356A1 - Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation - Google Patents

Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation Download PDF

Info

Publication number
WO2005102356A1
WO2005102356A1 PCT/US2005/012811 US2005012811W WO2005102356A1 WO 2005102356 A1 WO2005102356 A1 WO 2005102356A1 US 2005012811 W US2005012811 W US 2005012811W WO 2005102356 A1 WO2005102356 A1 WO 2005102356A1
Authority
WO
WIPO (PCT)
Prior art keywords
derivative
carotenoid
analog
subject
formulation
Prior art date
Application number
PCT/US2005/012811
Other languages
English (en)
French (fr)
Inventor
Samuel F. Lockwood
Sean O'malley
Henry Jackson
Geoff Nadolski
Original Assignee
Hawaii Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hawaii Biotech, Inc. filed Critical Hawaii Biotech, Inc.
Priority to CA002564066A priority Critical patent/CA2564066A1/en
Priority to EP05735338A priority patent/EP1750723A1/en
Publication of WO2005102356A1 publication Critical patent/WO2005102356A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
PCT/US2005/012811 2004-04-14 2005-04-14 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation WO2005102356A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002564066A CA2564066A1 (en) 2004-04-14 2005-04-14 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP05735338A EP1750723A1 (en) 2004-04-14 2005-04-14 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56219504P 2004-04-14 2004-04-14
US60/562,195 2004-04-14

Publications (1)

Publication Number Publication Date
WO2005102356A1 true WO2005102356A1 (en) 2005-11-03

Family

ID=34965679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012811 WO2005102356A1 (en) 2004-04-14 2005-04-14 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation

Country Status (4)

Country Link
US (1) US7691901B2 (US20050261254A1-20051124-C00068.png)
EP (1) EP1750723A1 (US20050261254A1-20051124-C00068.png)
CA (1) CA2564066A1 (US20050261254A1-20051124-C00068.png)
WO (1) WO2005102356A1 (US20050261254A1-20051124-C00068.png)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102576A1 (en) * 2005-03-23 2006-09-28 Cardax Pharmaceuticals, Inc. Water-dispersible carotenoids, including analogs and derivatives
WO2006105214A2 (en) * 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
WO2006119125A2 (en) * 2005-04-29 2006-11-09 Cardax Pharmaceuticals, Inc. Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates
WO2007027834A1 (en) * 2005-08-29 2007-03-08 Cardax Pharmaceuticals Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2007067957A1 (en) * 2005-12-07 2007-06-14 Cardax Pharmaceuticals, Inc. Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
US7247752B2 (en) 2004-10-01 2007-07-24 Cardax Pharmaceuticals, Inc. Methods for the synthesis of astaxanthin
EP1867327A1 (en) 2006-06-16 2007-12-19 Yamaha Hatsudoki Kabushiki Kaisha Astaxanthin and esters thereof for protecting neurocytes and treating Parkinson's disease
US9072314B2 (en) 2007-11-07 2015-07-07 Mead Johnson Nutrition Company Carotenoid-containing compositions and methods
JPWO2015178404A1 (ja) * 2014-05-20 2017-04-20 富士化学工業株式会社 カロテノイド誘導体、その薬学上許容される塩又はその薬学上許容されるエステル類若しくはアミド類
WO2020027304A1 (ja) * 2018-08-01 2020-02-06 アスタファーマシューティカルズ株式会社 新規カロテノイド関連誘導体、その塩又はエステル類若しくはアミド類

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
CA2495167C (en) * 2002-07-29 2018-08-21 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
JP2007254411A (ja) * 2006-03-24 2007-10-04 Tokyo Univ Of Pharmacy & Life Science アグリカナーゼ産生阻害剤
AU2009319860B2 (en) 2008-11-26 2016-07-21 Board Of Regents, The University Of Texas System A new family of pain producing substances and methods to produce novel analgesic drugs
US11055332B1 (en) 2010-10-08 2021-07-06 Google Llc Adaptive sorting of results
US9029342B2 (en) 2012-09-17 2015-05-12 Board Of Regents Of The University Of Texas System Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542632A1 (fr) * 1991-11-14 1993-05-19 LABORATOIRES ARKOPHARMA Société Anonyme Utilisation du beta-carotène dans le traitement de fond de l'asthme
DE19950327A1 (de) * 1998-10-19 2000-04-20 Werklust & Beheer Wassenaar B Ester von Karotinoiden zum Gebrauch bei der Verhütung und Behandlung von Augenkrankheiten
WO2002058682A2 (en) * 2001-01-23 2002-08-01 Lycored Natural Products Industries Ltd. An anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation
WO2003066583A1 (en) * 2002-02-06 2003-08-14 Dsm Ip Assets B.V. Astaxanthin esters
WO2004011423A2 (en) * 2002-07-29 2004-02-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354218A (en) 1963-05-10 1967-11-21 Hoffmann La Roche Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one
FR2076448A5 (US20050261254A1-20051124-C00068.png) 1970-01-15 1971-10-15 Rhone Poulenc Sa
US3989757A (en) 1973-08-29 1976-11-02 Hoffmann-La Roche Inc. Isomerizing cis-carotenoids to all-trans-carotenoids
US3965261A (en) 1975-04-29 1976-06-22 University Of Virginia Method for treating papillomas
US3975519A (en) 1975-06-09 1976-08-17 University Of Virginia Method for increasing the oxygen partial pressure in the bloodstream of mammals
US4070460A (en) 1975-11-10 1978-01-24 University Of Virginia Patents Foundation Method for treating cerebral edema
US4009270A (en) 1975-11-21 1977-02-22 The University Of Virginia Method for treating spinal cord injury
US4038144A (en) 1976-04-19 1977-07-26 The University Of Virginia Method of increasing fermentation yields
US4046880A (en) 1976-04-20 1977-09-06 The University Of Virginia Method of treating hypertension
JPS6053031B2 (ja) 1978-03-31 1985-11-22 武田薬品工業株式会社 スピロ化合物およびその製造方法
US4176179A (en) 1978-04-17 1979-11-27 The University Of Virginia Alumni Patents Foundation Method for treating arthritis
DE3048000A1 (de) 1980-12-19 1982-07-15 Basf Ag Stabile injizierbare (beta)-carotin-solubilisate und verfahren zu ihrer herstellung
US4491574A (en) 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
EP0151989B1 (de) 1984-01-28 1991-04-10 Roshdy Dr. Ismail Mittel zur Behandlung von Herzerkrankungen
US5346488A (en) 1985-04-08 1994-09-13 The General Hospital Corporation Laser-induced ablation of atherosclerotic plaque
EP0204987B1 (de) 1985-05-15 1991-11-21 Roshdy Dr. Ismail Vitamin E-haltiges Mittel zur Verbesserung der Eigenschaften des Blutes
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
CA2011651A1 (en) 1989-03-08 1990-09-08 Gerald Shklar Composition and method for inducing tumor regression
DE59003205D1 (de) 1989-07-25 1993-12-02 Hoffmann La Roche Verfahren zur Herstellung von Carotinoidpräparaten.
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
AU660630B2 (en) 1990-10-01 1995-07-06 Brigham And Women's Hospital Beta-carotene and vitamin E therapy for inhibition of major vascular events
US6132790A (en) 1991-09-06 2000-10-17 Betatene Limited Carotenoid composition
WO1993013660A1 (en) 1992-01-06 1993-07-22 Health Maintenance Programs, Inc. Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty
US5221668A (en) 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
IL104736A0 (en) 1992-03-27 1993-06-10 Zeagen Inc Method for producing beta-carotene using a fungal mated culture
US5328845A (en) 1992-03-27 1994-07-12 Universal Foods Corporation Fungal negative microorganism capable of producing high levels of beta-carotene
DE59306812D1 (de) 1992-04-14 1997-07-31 Hoffmann La Roche Präparate von fettlöslichen Substanzen
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
DE69327100T2 (de) 1992-06-04 2000-04-13 Betatene Pty Ltd Gemisch mit hohem gehalt an cis beta-carotin
GB9219524D0 (en) 1992-09-15 1992-10-28 Smithkline Beecham Plc Novel composition
US5310554A (en) 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
DE19609538A1 (de) 1996-03-11 1997-09-18 Basf Ag Feinverteilte Carotinoid- und Retinoidsuspensionen und Verfahren zu ihrer Herstellung
EP0689427B1 (en) 1993-03-22 2002-06-12 Cognis Australia Pty Ltd Water dispersible therapeutic carotenoid compounds
DK0689426T3 (da) 1993-03-22 2000-10-30 Cognis Australia Pty Ltd Terapeutisk middel til behandling af melanomer
US6218436B1 (en) 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
DE4322277A1 (de) 1993-07-05 1995-01-12 Basf Ag Verbessertes Verfahren zur Herstellung von Astaxanthin, neue Zwischenprodukte hierfür sowie ein Verfahren zu deren Herstellung
FR2707184B1 (fr) 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique.
US5607839A (en) 1993-07-22 1997-03-04 Nippon Oil Company, Ltd. Bacteria belonging to new genus process for production of carotenoids using same
CH685189A5 (de) 1993-11-19 1995-04-28 Marigen Sa Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamen Xanthophyll-Estern.
US6428816B1 (en) 1994-04-08 2002-08-06 Cognis Australia Pty., Ltd. Carotenoid agent for inhibiting the conversion of epithelial cells to tumors
JPH07300421A (ja) 1994-04-28 1995-11-14 Itano Reitou Kk 抗炎症剤
SE9401738D0 (sv) 1994-05-19 1994-05-19 Ewos Ab Bioactive feed
JPH0873312A (ja) 1994-09-02 1996-03-19 Noevir Co Ltd 皮膚外用剤
SE503336C2 (sv) 1994-09-19 1996-05-28 Asta Carotene Ab Medel och sätt för att öka produktionen av/hos fjäderfän
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
DE69511515T2 (de) 1994-12-21 2000-01-20 Hoffmann La Roche Carotenoide Ketone und Ester
US5643943A (en) 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5589468A (en) 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients
JPH10513444A (ja) 1995-02-03 1998-12-22 ビーエーエスエフ アクチェンゲゼルシャフト 皮膚疾患の治療のための医薬品の製造のためのカロチノイドの使用
JPH08337592A (ja) 1995-06-13 1996-12-24 Kaiyo Bio Technol Kenkyusho:Kk 新規カロテノイド
JPH0984591A (ja) 1995-09-26 1997-03-31 Kaiyo Bio Technol Kenkyusho:Kk カロテノイド硫酸エステルおよびその製造方法
US6060511A (en) 1995-10-05 2000-05-09 Gainer; John L. Trans-sodium crocetinate, methods of making and methods of use thereof
JP4115524B2 (ja) 1995-10-17 2008-07-09 昭和電工株式会社 高純度トコフェロールリン酸エステル類、その製造方法、その分析方法並びに化粧料
JPH09124470A (ja) 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物
US5854015A (en) 1995-10-31 1998-12-29 Applied Food Biotechnology, Inc. Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
US5827539A (en) 1995-12-28 1998-10-27 Amway Corporation Dry carotenoid-oil powder and process for making same
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5837224A (en) 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
JPH09202730A (ja) 1996-01-24 1997-08-05 Nippon Mektron Ltd 発ガン抑制作用剤
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
DE19609476A1 (de) 1996-03-11 1997-09-18 Basf Ag Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen
DE19609477A1 (de) 1996-03-11 1997-09-18 Basf Ag Stabile wäßrige Solubilisate von Carotinoiden und Vitamine
SE506191C2 (sv) 1996-03-27 1997-11-17 Astacarotene Ab Medel och sätt för att öka produktionen av/hos däggdjur
DE69728206T2 (de) 1996-05-14 2005-03-10 Dsm Ip Assets B.V. Herstellungsverfahren für Carotenoid-Zusammensetzungen
DE19637517A1 (de) 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
JPH10155459A (ja) 1996-11-27 1998-06-16 Suntory Ltd アスタキサンチン含有飲食物
DE19649062A1 (de) 1996-11-27 1998-05-28 Basf Ag Flüssige, mit Öl mischbare Carotinoid-Zubereitungen
WO1998029111A1 (fr) 1996-12-25 1998-07-09 Designer Foods Association Ltd. Inhibiteurs de la carcinogenese
SE522246C2 (sv) 1997-02-27 2004-01-27 Astacarotene Ab Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion
ATE530180T1 (de) 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
US5858700A (en) 1997-04-03 1999-01-12 Kemin Foods, Lc Process for the isolation and purification of lycopene crystals
EP0984915A4 (en) 1997-04-04 2002-11-27 Henkel Corp LUTEINE ESTERS WITH HIGH BIOAVAILABILITY
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5876782A (en) 1997-05-14 1999-03-02 Kemin Industries, Inc. Method for the conversion of xanthophylls in plant material
JPH10327865A (ja) 1997-05-29 1998-12-15 Kirin Brewery Co Ltd カロテノイド配糖体およびその製造法
SE512531C2 (sv) 1997-09-04 2000-03-27 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
US5959138A (en) 1997-11-25 1999-09-28 Industrial Organica S.A. De C.V. Short chain diesters and process for making the same
SE511237C2 (sv) 1997-12-16 1999-08-30 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor
US6020003A (en) 1998-02-23 2000-02-01 Basf Corporation Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin
US6051587A (en) 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6043259A (en) 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US6075058A (en) 1998-12-12 2000-06-13 Tufts University Compositions for increased bioavailability of carotenoids
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
JP4491090B2 (ja) 1999-10-08 2010-06-30 ヒガシマル醤油株式会社 アポトーシス誘導剤
US6344214B1 (en) 1999-12-13 2002-02-05 Cyanotech Corporation Method for retarding and ameliorating fever blisters and canker sores
US6258855B1 (en) 2000-02-08 2001-07-10 Cyanotech Corporation Method of retarding and ameliorating carpal tunnel syndrome
US6579544B1 (en) 2000-05-31 2003-06-17 Nutriex, L.L.C. Method for supplementing the diet
US20020110604A1 (en) 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
WO2002047680A2 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
ES2300441T3 (es) 2001-02-23 2008-06-16 Luis W. Levy Esteres de carotenoides novedosos.
GB0119052D0 (en) 2001-08-03 2001-09-26 Mars Uk Ltd Foodstuff
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542632A1 (fr) * 1991-11-14 1993-05-19 LABORATOIRES ARKOPHARMA Société Anonyme Utilisation du beta-carotène dans le traitement de fond de l'asthme
DE19950327A1 (de) * 1998-10-19 2000-04-20 Werklust & Beheer Wassenaar B Ester von Karotinoiden zum Gebrauch bei der Verhütung und Behandlung von Augenkrankheiten
WO2002058682A2 (en) * 2001-01-23 2002-08-01 Lycored Natural Products Industries Ltd. An anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation
WO2003066583A1 (en) * 2002-02-06 2003-08-14 Dsm Ip Assets B.V. Astaxanthin esters
WO2004011423A2 (en) * 2002-07-29 2004-02-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARDOUNEL ARTURO J ET AL: "Direct superoxide anion scavenging by a disodium disuccinate astaxanthin derivative: Relative efficacy of individual stereoisomers versus the statistical mixture of stereoisomers by electron paramagnetic resonance imaging.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1 AUG 2003, vol. 307, no. 3, 1 August 2003 (2003-08-01), pages 704 - 712, XP002343417, ISSN: 0006-291X *
FREY, DEAN A. ET AL: "The Efficient Synthesis of Disodium Disuccinate Astaxanthin ( Cardax )", ORGANIC PROCESS RESEARCH & DEVELOPMENT , 8(5), 796-801 CODEN: OPRDFK; ISSN: 1083-6160, September 2004 (2004-09-01), XP002343418 *
HIX LAURA M ET AL: "Upregulation of connexin 43 protein expression and increased gap junctional communication by water soluble disodium disuccinate astaxanthin derivatives.", CANCER LETTERS. 28 JUL 2004, vol. 211, no. 1, 28 July 2004 (2004-07-28), pages 25 - 37, XP002343419, ISSN: 0304-3835 *
SHOWALTER LORI A ET AL: "Plasma appearance and tissue accumulation of non-esterified, free astaxanthin in C57BL/6 mice after oral dosing of a disodium disuccinate diester of astaxanthin (Heptax).", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. TOXICOLOGY & PHARMACOLOGY : CBP. MAR 2004, vol. 137, no. 3, March 2004 (2004-03-01), pages 227 - 236, XP002343416, ISSN: 1532-0456 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247752B2 (en) 2004-10-01 2007-07-24 Cardax Pharmaceuticals, Inc. Methods for the synthesis of astaxanthin
WO2006102576A1 (en) * 2005-03-23 2006-09-28 Cardax Pharmaceuticals, Inc. Water-dispersible carotenoids, including analogs and derivatives
WO2006105214A2 (en) * 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
WO2006105214A3 (en) * 2005-03-29 2007-02-22 Hawaii Biotech Inc Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
WO2006119125A2 (en) * 2005-04-29 2006-11-09 Cardax Pharmaceuticals, Inc. Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates
WO2006119125A3 (en) * 2005-04-29 2007-01-11 Hawaii Biotech Inc Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates
WO2007027834A1 (en) * 2005-08-29 2007-03-08 Cardax Pharmaceuticals Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2007067957A1 (en) * 2005-12-07 2007-06-14 Cardax Pharmaceuticals, Inc. Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
EP1867327A1 (en) 2006-06-16 2007-12-19 Yamaha Hatsudoki Kabushiki Kaisha Astaxanthin and esters thereof for protecting neurocytes and treating Parkinson's disease
US9072314B2 (en) 2007-11-07 2015-07-07 Mead Johnson Nutrition Company Carotenoid-containing compositions and methods
JPWO2015178404A1 (ja) * 2014-05-20 2017-04-20 富士化学工業株式会社 カロテノイド誘導体、その薬学上許容される塩又はその薬学上許容されるエステル類若しくはアミド類
EP3147279A4 (en) * 2014-05-20 2018-01-10 Fuji Chemical Industry Co., Ltd. Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof
US10125104B2 (en) 2014-05-20 2018-11-13 Asta Pharmaceuticals Co., Ltd. Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof
AU2015262405B2 (en) * 2014-05-20 2019-01-03 Asta Pharmaceuticals Co., Ltd. Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof
WO2020027304A1 (ja) * 2018-08-01 2020-02-06 アスタファーマシューティカルズ株式会社 新規カロテノイド関連誘導体、その塩又はエステル類若しくはアミド類

Also Published As

Publication number Publication date
US20050261254A1 (en) 2005-11-24
EP1750723A1 (en) 2007-02-14
CA2564066A1 (en) 2005-11-03
US7691901B2 (en) 2010-04-06

Similar Documents

Publication Publication Date Title
US7691901B2 (en) Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US9180111B2 (en) Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
US7317008B2 (en) Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20060276372A1 (en) Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
US7521584B2 (en) Carotenoid analogs or derivatives for the inhibition and amelioration of disease
EP1957057A1 (en) Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
US7723327B2 (en) Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7345091B2 (en) Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050009788A1 (en) Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050026874A1 (en) Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050148517A1 (en) Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050059635A1 (en) Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050049248A1 (en) Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20070015735A1 (en) Water-dispersible carotenoids, including analogs and derivatives
US20060270589A1 (en) Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2564066

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005735338

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005735338

Country of ref document: EP